Status:
COMPLETED
The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)
Lead Sponsor:
Jichi Medical University
Conditions:
Hypertension
Eligibility:
All Genders
30-85 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate which combination therapy is more effective for improving the blood pressure (BP) and reducing target organ damage in Japanese hypertensive patients: Angiot...
Detailed Description
Renin-angiotensin (RA) inhibitors have been demonstrated to be the most effective drugs for reducing subclinical target organ damage in hypertensive patients. In several patients, however, BP control ...
Eligibility Criteria
Inclusion
- Hypertensive outpatients aged 30 years or older, and less than 85 years (at the time of informed consent), regardless of sex
- Office systolic BP/diastolic BP \> 140/90 mmHg in a sitting position even if on treatment with olmesartan 20 mg/day for 3 months.
Exclusion
- Secondary hypertension or malignant hypertension
- History of myocardial infarction or cerebrovascular accidents within 6 months prior to the screening
- Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG) done within 6 months of screening or scheduled
- Current treatment for congestive cardiac failure (New York Heart Association \[NYHA\] functional class II or severer) or ejection fraction \<40%
- Atrial fibrillation or atrial flutter
- Renal dysfunction (serum creatinine ≥2 mg/dl)
- Hepatic dysfunction (AST and/or ALT ≥100 IU/l)
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00607035
Start Date
May 1 2006
End Date
May 1 2008
Last Update
November 20 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jichi Medical University School of Medicine
Tochigi, Japan